Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study

Robert M. Jacobson, Adedunni Adegbenro, V. Shane Pankratz, Gregory A. Poland

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The recent setback in the development of a safe and effective rotavirus vaccine illustrates an important problem regarding prelicensure testing and its ability to identify rare vaccine-related adverse effects. It is our contention that the possibility of a rare but serious vaccine adverse effect is difficult to detect in prelicensure testing. In this paper, we review the history regarding the testing and eventual studies that led to the permanent withdrawal of that vaccine. The post-licensure discovery of a serious adverse event associated with the rotavirus vaccine is not unique among vaccines, but represents a recurrent phenomenon that in fact is mathematically predictable. Prelicensure studies examine thousands of subjects and not hundreds of thousands. A sample size of 10,000 subjects may provide excellent estimates of efficacy, but cannot provide an adequate denominator to rule out rare adverse events. It lacks the power. Just as with the rotavirus vaccine, only after hundreds of thousands of doses of vaccines are distributed, will such rare events appear often enough to permit detection. For that reason, we must depend upon the modern post-licensure surveillance programs that we already have in place.

Original languageEnglish (US)
Pages (from-to)2428-2433
Number of pages6
JournalVaccine
Volume19
Issue number17-19
DOIs
StatePublished - Mar 21 2001

Fingerprint

Licensure
Rotavirus Vaccines
Vaccination
Vaccines
vaccination
vaccines
Rotavirus
Sample Size
adverse effects
History
testing
history
monitoring
dosage

Keywords

  • Detection
  • Prelicensure testing
  • Rotavirus vaccine
  • Sample size
  • Serious vaccine adverse effects

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. / Jacobson, Robert M.; Adegbenro, Adedunni; Pankratz, V. Shane; Poland, Gregory A.

In: Vaccine, Vol. 19, No. 17-19, 21.03.2001, p. 2428-2433.

Research output: Contribution to journalArticle

Jacobson, Robert M. ; Adegbenro, Adedunni ; Pankratz, V. Shane ; Poland, Gregory A. / Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. In: Vaccine. 2001 ; Vol. 19, No. 17-19. pp. 2428-2433.
@article{ecdd3e2516594de58e95a272247072ed,
title = "Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study",
abstract = "The recent setback in the development of a safe and effective rotavirus vaccine illustrates an important problem regarding prelicensure testing and its ability to identify rare vaccine-related adverse effects. It is our contention that the possibility of a rare but serious vaccine adverse effect is difficult to detect in prelicensure testing. In this paper, we review the history regarding the testing and eventual studies that led to the permanent withdrawal of that vaccine. The post-licensure discovery of a serious adverse event associated with the rotavirus vaccine is not unique among vaccines, but represents a recurrent phenomenon that in fact is mathematically predictable. Prelicensure studies examine thousands of subjects and not hundreds of thousands. A sample size of 10,000 subjects may provide excellent estimates of efficacy, but cannot provide an adequate denominator to rule out rare adverse events. It lacks the power. Just as with the rotavirus vaccine, only after hundreds of thousands of doses of vaccines are distributed, will such rare events appear often enough to permit detection. For that reason, we must depend upon the modern post-licensure surveillance programs that we already have in place.",
keywords = "Detection, Prelicensure testing, Rotavirus vaccine, Sample size, Serious vaccine adverse effects",
author = "Jacobson, {Robert M.} and Adedunni Adegbenro and Pankratz, {V. Shane} and Poland, {Gregory A.}",
year = "2001",
month = "3",
day = "21",
doi = "10.1016/S0264-410X(00)00467-9",
language = "English (US)",
volume = "19",
pages = "2428--2433",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17-19",

}

TY - JOUR

T1 - Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study

AU - Jacobson, Robert M.

AU - Adegbenro, Adedunni

AU - Pankratz, V. Shane

AU - Poland, Gregory A.

PY - 2001/3/21

Y1 - 2001/3/21

N2 - The recent setback in the development of a safe and effective rotavirus vaccine illustrates an important problem regarding prelicensure testing and its ability to identify rare vaccine-related adverse effects. It is our contention that the possibility of a rare but serious vaccine adverse effect is difficult to detect in prelicensure testing. In this paper, we review the history regarding the testing and eventual studies that led to the permanent withdrawal of that vaccine. The post-licensure discovery of a serious adverse event associated with the rotavirus vaccine is not unique among vaccines, but represents a recurrent phenomenon that in fact is mathematically predictable. Prelicensure studies examine thousands of subjects and not hundreds of thousands. A sample size of 10,000 subjects may provide excellent estimates of efficacy, but cannot provide an adequate denominator to rule out rare adverse events. It lacks the power. Just as with the rotavirus vaccine, only after hundreds of thousands of doses of vaccines are distributed, will such rare events appear often enough to permit detection. For that reason, we must depend upon the modern post-licensure surveillance programs that we already have in place.

AB - The recent setback in the development of a safe and effective rotavirus vaccine illustrates an important problem regarding prelicensure testing and its ability to identify rare vaccine-related adverse effects. It is our contention that the possibility of a rare but serious vaccine adverse effect is difficult to detect in prelicensure testing. In this paper, we review the history regarding the testing and eventual studies that led to the permanent withdrawal of that vaccine. The post-licensure discovery of a serious adverse event associated with the rotavirus vaccine is not unique among vaccines, but represents a recurrent phenomenon that in fact is mathematically predictable. Prelicensure studies examine thousands of subjects and not hundreds of thousands. A sample size of 10,000 subjects may provide excellent estimates of efficacy, but cannot provide an adequate denominator to rule out rare adverse events. It lacks the power. Just as with the rotavirus vaccine, only after hundreds of thousands of doses of vaccines are distributed, will such rare events appear often enough to permit detection. For that reason, we must depend upon the modern post-licensure surveillance programs that we already have in place.

KW - Detection

KW - Prelicensure testing

KW - Rotavirus vaccine

KW - Sample size

KW - Serious vaccine adverse effects

UR - http://www.scopus.com/inward/record.url?scp=0035925654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035925654&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(00)00467-9

DO - 10.1016/S0264-410X(00)00467-9

M3 - Article

VL - 19

SP - 2428

EP - 2433

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-19

ER -